DK1073738T3 - Human K+-ionkanal og terapeutiske applikationer deraf - Google Patents

Human K+-ionkanal og terapeutiske applikationer deraf

Info

Publication number
DK1073738T3
DK1073738T3 DK99920731T DK99920731T DK1073738T3 DK 1073738 T3 DK1073738 T3 DK 1073738T3 DK 99920731 T DK99920731 T DK 99920731T DK 99920731 T DK99920731 T DK 99920731T DK 1073738 T3 DK1073738 T3 DK 1073738T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
ion channel
methods
present
relates
Prior art date
Application number
DK99920731T
Other languages
English (en)
Inventor
Walter Stuehmer
Synnoeve Beckh
Camino Fernandez-Miranda D Del
Ruediger Weseloh
Luis Angel Pardo-Fernandez
Andrea Brueggemann
Perez Araceli Sanchez
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK1073738T3 publication Critical patent/DK1073738T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99920731T 1998-04-21 1999-04-21 Human K+-ionkanal og terapeutiske applikationer deraf DK1073738T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98107268 1998-04-21
PCT/EP1999/002695 WO1999054463A2 (en) 1998-04-21 1999-04-21 Human k+ ion channel and therapeutic applications thereof

Publications (1)

Publication Number Publication Date
DK1073738T3 true DK1073738T3 (da) 2005-01-24

Family

ID=8231794

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99920731T DK1073738T3 (da) 1998-04-21 1999-04-21 Human K+-ionkanal og terapeutiske applikationer deraf

Country Status (10)

Country Link
US (7) US6638736B1 (da)
EP (1) EP1073738B1 (da)
JP (2) JP2002512029A (da)
AT (1) ATE278017T1 (da)
CA (1) CA2323571A1 (da)
DE (1) DE69920681T2 (da)
DK (1) DK1073738T3 (da)
ES (1) ES2230852T3 (da)
PT (1) PT1073738E (da)
WO (1) WO1999054463A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1073738E (pt) * 1998-04-21 2005-01-31 Max Planck Ges Forderung Der W Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas
DE10025620A1 (de) * 2000-05-24 2001-12-06 Forschungsgesellschaft Genion Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten
DE10224534A1 (de) * 2002-05-31 2003-12-11 Juergen Dolderer Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung
WO2006037611A2 (en) * 2004-10-01 2006-04-13 Centro De Investigación Y De Estudios Avanzados Del Ipn Methods for the early diagnosis of viral infections, inflammatory diseases, a predisposition for proliferative disorders or hyperplasia by analysing eag or erg expression levels
WO2006037604A1 (en) * 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
AU2013201604B2 (en) * 2007-04-13 2014-08-14 Southern Research Institute Anti-angiogenic agents and methods of use
ES2334084B1 (es) * 2007-12-21 2011-01-24 Inst Cientifico Tecnol Navarra Marcadores geneticos para el pronostico de la esclerosis multiple.
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
TWI570415B (zh) * 2015-10-02 2017-02-11 A spring probe having an outer sleeve and a probe device having the spring probe
EP3195727A1 (en) 2016-01-22 2017-07-26 Forschungsinstitut Fur Biologischen Landbau (FiBL) Duddingtonia flagrans strain and feed additive formulation for biological pest control

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
CA2258513A1 (en) * 1996-07-02 1998-01-08 Beat Schmid Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
US6610827B1 (en) * 1997-10-29 2003-08-26 Elan Pharmaceuticals, Inc. Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor
PT1073738E (pt) * 1998-04-21 2005-01-31 Max Planck Ges Forderung Der W Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas

Also Published As

Publication number Publication date
US7129207B2 (en) 2006-10-31
ES2230852T3 (es) 2005-05-01
WO1999054463A3 (en) 2000-04-20
CA2323571A1 (en) 1999-10-28
ATE278017T1 (de) 2004-10-15
PT1073738E (pt) 2005-01-31
US6638736B1 (en) 2003-10-28
DE69920681T2 (de) 2005-09-08
US20080020406A1 (en) 2008-01-24
US7364730B2 (en) 2008-04-29
US7314914B2 (en) 2008-01-01
EP1073738A2 (en) 2001-02-07
JP2002512029A (ja) 2002-04-23
US20030077735A1 (en) 2003-04-24
DE69920681D1 (de) 2004-11-04
US7364845B2 (en) 2008-04-29
WO1999054463A2 (en) 1999-10-28
EP1073738B1 (en) 2004-09-29
US20030087377A1 (en) 2003-05-08
US20030087378A1 (en) 2003-05-08
JP2009235091A (ja) 2009-10-15
US20030092120A1 (en) 2003-05-15
US20100021467A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
Yin et al. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling
Rao et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase
Zhang et al. Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2
Holtick et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis
Lv et al. Scutellarin inhibits hypoxia‐induced epithelial‐mesenchymal transition in bladder cancer cells
BR0312913A (pt) Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo
Shou et al. Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells
Ahmed et al. Combinatory Effects of Bone Marrow‐Derived Mesenchymal Stem Cells and Indomethacin on Adjuvant‐Induced Arthritis in Wistar Rats: Roles of IL‐1β, IL‐4, Nrf‐2, and Oxidative Stress
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
DK0836485T3 (da) Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
DK0910647T3 (da) Human DNase i hyperaktive varianter
ATE236258T1 (de) Gelonin und einen antikörper entahltende immuntoxine
Pozzi et al. MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression
Zheng et al. Destabilization of macrophage migration inhibitory factor by 4‐IPP reduces NF‐κB/P‐TEFb complex‐mediated c‐Myb transcription to suppress osteosarcoma tumourigenesis
Heo et al. Radiation-induced matrix metalloproteinases limit natural killer cell-mediated anticancer immunity in NCI-H23 lung cancer cells
Hou et al. The inhibitory effect of IFN-γ on protease HTRA1 expression in rheumatoid arthritis
Fritsch et al. TNF induced cleavage of HSP90 by cathepsin D potentiates apoptotic cell death
ATE278017T1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
Welk et al. Proteasome activator PA200 regulates myofibroblast differentiation
BRPI0407544A (pt) derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem
Xie et al. Inhibiting necroptosis of spermatogonial stem cell as a novel strategy for male fertility preservation
BR0215063A (pt) Derivados de hidroxifenil-pirazol ativos como inibidores de cinase, processo para preparação dos mesmos e composições farmacêuticas compreendendo-os
Gelati et al. Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis
Fernandez-Rojo et al. Gomesin peptides prevent proliferation and lead to the cell death of devil facial tumour disease cells
Scott et al. N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties